Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Usefulness of Soluble Urokinase Plasminogen Activator Receptor to Predict Repeat Myocardial Infarction and Mortality in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Intervention

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Causes of Mortality in the Marfan Syndrome(from a Nationwide Register Study)

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Usefulness of Transcatheter Aortic Valve Implantation for Treatment of Pure Native Aortic Valve Regurgitation

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Prevalence of infective endocarditis in patients with positive blood cultures: a Danish nationwide study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Partial Oral Therapy for Osteomyelitis and Endocarditis. Reply

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. In-hospital metabolite changes in infective endocarditis-a longitudinal 1H NMR-based study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Prevalence of Infective Endocarditis in Enterococcus faecalis Bacteremia

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Repeatability and Reproducibility of Neonatal Echocardiography: The Copenhagen Baby Heart Study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
The plasma level of the inflammatory biomarker soluble urokinase plasminogen activator receptor (suPAR) is an independent predictor of cardiovascular disease and all-cause mortality in healthy subjects. The prognostic capability of suPAR, its temporal course, and its relation to plasma C-reactive protein (CRP) in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous intervention (PCI) is unknown. Therefore, the plasma suPAR and CRP levels were measured in 296 consecutive patients with ST-segment elevation myocardial infarction admitted for primary PCI at baseline and every 6 to 8 hours thereafter until the cardiac biomarker levels had peaked. The end points were all-cause mortality and fatal or nonfatal recurrent myocardial infarction (MI). During a median follow-up period of 5.75 years, 69 deaths and 48 nonfatal and 14 fatal recurrent MIs occurred. All-cause mortality increased significantly from 8.1% to 41.5% across increasing quartiles of suPAR levels at the end of follow-up (log-rank p
Original languageEnglish
JournalAmerican Journal of Cardiology
Volume110
Issue number12
Pages (from-to)1756-63
Number of pages8
ISSN0002-9149
DOIs
Publication statusPublished - 2012

ID: 36609982